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Abstract
Albumin, an abundant plasma protein with multifunctional properties, is mainly synthesized in the liver. Albumin has been
implicated in Alzheimer’s disease (AD) since it can bind to and transport amyloid beta (Ab), the causative agent of AD;
albumin is also a potent inhibitor of Ab polymerization. Despite evidence of non-hepatic transcription of albumin in many
tissues including kidney and pancreas, non-hepatic synthesis of albumin at the protein level has been rarely confirmed. In a
pilot phase study of Human Brain Proteome Project, we found evidence that microglial cells in brain may synthesize
albumin. Here we report, for the first time, the de novo synthesis of albumin in human microglial cells in brain. Furtherore,
we demonstrate that the synthesis and secretion of albumin from microglial cells is enhanced upon microgial activation by
Ab1–42- or lipopolysaccharide (LPS)-treatment. These data indicate that microglial cells may play a beneficial role in AD by
secreting albumin that not only inhibits Ab polymerization but also increases its clearance.
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Introduction
Albumin is the most abundant plasma protein with multifunc-
tional properties such as ligand-binding and transport, maintaining
the colloid osmotic pressure of plasma, and regulating neutrophil
function [1]. Clinically, albuminhas beenextensively used incritical
conditions including vascular collapse in severely ill patients and
cirrhosis [2]. Recently, it has been also suggested that albumin
specifically bind to low molecular weight molecules that might be
important diagnostic or prognostic indicators of diseases [3].
Albumin is not only a high-abundance protein in plasma, but
also a major component of most extracellular fluids including
interstitial fluid, lymph, and cerebrospinal fluid (CSF) [4–7] since
it enters tissues and organs from blood. For example, albumin
enters brain across blood-brain barrier by molecular diffusion [8].
Albumin is found at a low concentration (,0.2 g/L) in CSF, yet it
amounts to ,80% of the total CSF protein in contrast to ,60% as
in plasma [1]. CSF serum quotient of albumin, along with other
blood-derived proteins in CSF, is widely used in the diagnosis of
neurological diseases [9]. Albumin has been implicated in
Alzheimer’s disease (AD) because it can specifically bind to and
transport amyloid beta (Ab), the causative agent of AD [10], under
physiological conditions [11]. Moreover, albumin is a potent
inhibitor of Ab polymerization, representing ,60% of amyloid
inhibitory activity in CSF and plasma [12].
Albumin is mainly synthesized in the liver at a rate of ,12 g per
day, representing ,25% of total hepatic protein synthesis [13].
Non-hepatic transcription of albumin has been reported in kidney
and pancreas [14], as well as in intestine, lymph gland, testicle,
uterus, tongue, and mammary gland [15]. Despite the evidence of
non-hepatic transcription of albumin in many tissues, non-hepatic
synthesis of albumin at the protein level has been rarely confirmed.
For example, albumin in thyroid gland was found to originate
from blood rather than by de novo synthesis [16]. Also, cell-bound
albumin, present on the surface of lymphocytes and macrophages,
was found to originate either from the tissue culture medium in
vitro or from serum in vivo [17]. Recently, Yamaguchi et al. [18]
provided convincing evidence of albumin synthesis in bone tissues
cultured in serum-, albumin-free medium. There has been no
specific report about the synthesis of albumin in brain either at the
mRNA level or at the protein level.
In a pilot phase study of Human Brain Proteome Project, we
found evidence that microglial cells in brain may synthesize
albumin. To further confirm this finding, we examined the
expression of albumin in human microglial cells and brain tissues.
Results and Discussion
To provide evidence of albumin synthesis in human microglial
cells, three biospecimens were used: 1) immortalized human
microglial cell line (HMO6); 2) human primary microglial cells; 3)
human fetal and adult brain tissues. Additionally, Alzheimer’s
brain tissues were used to show the increased synthesis of albumin
in microglial cells in AD.
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human cells and brain tissues to confirm that albumin is expressed
in microglial cells both in vitro and in vivo. In immunocytochem-
istry (ICC), all HMO6 cells were double-positive for microglial
markers (CD11b [19] and Iba1 [20]) and albumin (Fig. 1a); human
primary microglial cells staining positive for Iba1 coexpressed
albumin (Fig. 1b). In immunohistochemistry (IHC) study using
human fetal and adult brain tissues, cells staining positive for
microglial markers (CD11b and Iba1), also coexpressed albumin
(Fig. 1c&d). When human adult brain tissues were double stained
for albumin and non-microglial cell markers (i.e. microtubule-
associated protein 2 (MAP2) for neurons; glial fibrillary acidic
protein (GFAP) for astrocytes; myelin basic protein (MBP) for
oligodendrocytes), minimal co-localization was observed (Fig. 1e–g).
To further confirm that albumin detected in HMO6 cells is not
bovine albumin from the incubation media but human albumin,
peptide sequencing using tandem mass spectrometry (MS/MS)
was performed, which provided clear evidence that the albumin in
HMO6 cells is human origin (Fig. 2). The list of tryptic peptides
identified using MS/MS is summarized in Table S1.
HMO6 cells were activated by either Ab1–42 or lipopolysac-
charide (LPS) as previously described [21]. Interestingly, the levels
of albumin mRNA and protein increased upon microglial
activation by Ab1–42- or LPS- treatments (Fig. 3). According to
quantitative real-time PCR results, albumin gene transcription in
HMO6 cells was more responsive to Ab1–42 than to LPS (Fig. 3a),
which did not correlate well with albumin protein synthesis as
illustrated by immunoblot analysis using HMO6 cell lysates
Figure 1. Albumin expression in human microglial cells. Microglial markers (CD11b or Iba-1) were co-expressed with albumin in all HMO6 cells
(a) and human primary microglial cells (b). This observation was further confirmed by immunohistochemical staining of human fetal (c) and adult (d)
brain tissues, in which albumin was co-expressed with CD11b or Iba-1. Anti-human-albumin antibody used for ICC and IHC does not have cross-
reactivity with bovine albumin. Minimal co-localization of albumin and non-microglial markers was observed in other cell types of brain: MAP2 for
neurons (e); GFAP for astrocytes (f); MBP for oligodendrocytes (g). Scale bars=50 mm.
doi:10.1371/journal.pone.0002829.g001
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HMO6 cells is not bovine but human origin. The peptide QNCELFEQLGEYK is human-specific (i.e. the sequence is not 100% homologous with its
bovine homologue, and thus distinguishable using MS/MS. The list of tryptic peptides identified using MS/MS is summarized in Table S1. b and y
represent b ions and y ions respectively, which are generated during peptide fragmentation in MS/MS [29].
doi:10.1371/journal.pone.0002829.g002
Figure 3. Increase in albumin synthesis and secretion after microglial activation by Ab1–42- or LPS-treatments. qRT-PCR data (a) show
that the transcription of albumin gene is significantly enhanced after microglial activation by Ab1–42- or LPS-treatment. Immunoblot data also show
that albumin synthesis increases at the protein level after microglial activation (b). In addition, immunoblot data show that anti-human-albumin
antibody used does not have any cross-reactivity with bovine albumin, and that albumin is present in the incubation medium (i.e. thus secreted from
cells). ELISA data show that albumin secretion from HMO6 cells increased significantly after microglial activation (c). Moreover, the level of albumin in
the incubation medium of Ab1–42-treated cells was significantly higher than that of LPS-treated cells. This observation partly explains why the increase
of albumin expression at the mRNA level is not reflected well at the protein level. Since albumin is directly secreted from cells after synthesis, the
increase of albumin expression seems to be reflected better in the incubation media than in cell lysates.
doi:10.1371/journal.pone.0002829.g003
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directly secreted from cells after synthesis. In accordance with this
explanation, the level of albumin secreted by HMO6 cells into the
incubation media also increased significantly after microglial
activation, and was more responsive to Ab1–42 than LPS (Fig. 3c).
The synthesis of albumin by microglial cells provides a
convincing explanation why the proportion of albumin in CSF is
higher than that in plasma. Since all blood proteins traverse blood-
brain barrier by passive diffusion, larger molecules such as
albumin are slower in exchange according to the laws of diffusion,
and thus the relative proportion of albumin in CSF should be
lower than that in plasma [22]. On the contrary, the proportion of
albumin in CSF (,80%) is higher than that in plasma (,60%),
which may be explained by de novo synthesis of albumin in brain by
microglial cells. The important and diverse roles of albumin in
extracellular fluids underscore the roles of microglial cells in
maintaining microenvironments of brain under physiological
conditions.
Our data also show that the expression level of albumin in
microglial cells increases upon activation with Ab1–42- or LPS-
treatments. Microglial cells have been implicated in AD mainly
because of their markedly elevated distribution in brain regions
with Ab deposition, and their pro-inflammatory functions [23].
Despite all the circumstantial evidence against microglial involve-
ment in AD, it is still not clear whether microglial cells are ‘friends
or foes’ in AD [24]. Our findings suggest that microglial cells may
diminish Ab deposition by increasing albumin synthesis and
secretion. The capacity to bind to and transport Ab enables
albumin to inhibit Ab polymerization and to increase Ab
clearance [12,25] (Fig. 4). These findings indicate that microglial
cells may play a beneficial role in AD in which the ‘amyloid
hypothesis’ that Ab aggregates to trigger a complex pathologic
cascade leading to neurodegeneration is generally accepted [26].
Materials and Methods
Cell culture
For in vitro study, immortalized human microglial cell line (HMO6)
was used [21]. HMO6 cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM, Gibco) with high glucose supplemented
with 10% fetal bovine serum (FBS, Gibco) and 20 mg/ml gentamicin
(Sigma), and incubated at 37uCa n d5 %C O 2.L P Sa n dA b1–42 were
acquired from Sigma-Aldrich and added to HMO6 cells at a
concentration of 100 ng/mL and 5 mM, respectively. Either LPS- or
Ab1–42-treated HMO6 cells were harvested 6 hrs after treatment for
further analysis except ELISA in which the incubation media were
collected along 12 hrs time course for analysis.
Primary human microglial cell culture
Primary human microglial cells were prepared from embryonic
human brains of 12–15 weeks gestation as previously described
[21]. The use of embryonic tissue samples were approved by
Ethics Committee of the University of British Columbia, Faculty
of Medicine. Briefly, brain tissues were incubated in phosphate-
buffered saline (PBS) containing 0.25% trypsin and 40 mg/ml
DNase I for 30 min at 37uC. Dissociated cells were suspended in
DMEM supplemented with 5% FBS, 5% horse serum, 20 mg/ml
gentamicin, and 2.5 mg/ml amphotericine B (feeding medium),
plated at a density of 10
6 cells/ml in 10 cm culture dish (10 ml),
and incubated at 37uC in an incubator with 5% CO2/95% air
atmosphere. After 2–3 weeks in vitro, microglia-enriched cultures
were prepared by harvesting the floating cells in culture dish and
replating them on Lab-Tek II Chamber Slide System (210
4 cells/
wells, Nunc) for immunocytochemistry.
Immunoblot
Cell lysates were prepared with lysis buffer containing 7M urea,
2M thiourea, and 4% CHAPS. 2 ml of the incubation medium
was harvested, centrifuged at 1500 rpm for 10 minutes, and the
supernatant was concentrated to about 15 ml using an Amicon
centrifugal filter with 10-kDa nominal molecular weight limit
(Millipore). Cell lysates, the incubation medium concentrate, and
FBS were separated in 4–12% polyacrylamide gels (Invitrogen)
and transferred to nitrocellulose membrane. The primary
antibodies used were anti-human-albumin (1:1000, Abcam) that
does not have cross-reactivity with bovine albumin, and anti-b-
actin (1:1000, Cell Signaling).
Quantitative real-time PCR (qRT-PCR)
RNA was isolated from six biological replicates from each group
using Qiagen RNeasy MiniKit (Qiagen), pooled, and subjected to
first-strand cDNA synthesis using Reverse Transcription System
(Promega) according to the manufacturer’s protocol. qRT-PCR was
performed using Rotor-Gene 6000 (Corbett Lifescience), threshold
cycle number and reaction efficiency were determined using Rotor-
Gene 6000 series software version 2.7, and the 2
2DDCTm e t h o dw a s
used for relative quantitation. The primers used were: 59-
ATGCCCCGGAACTCCTTTTC -39 (forward) and 59-CAA-
CAGGCAGGCAGCTTTAT -39 (reverse) for albumin, and 59-
CTAGAAGCATTTGCGGTGGACGATGGAGGG -39 (forward)
and 59-TGACGGGGTCACCCACACACTGTGCCCATCTA -39
(reverse) for GAPDH.
Enzyme-Linked Immunosorbent Assay (ELISA)
The amount of albumin in the cell incubation media was
determined by human albumin BioAssay ELISA kit (US
Biological). Six biological replicates were used, and each replicate
was measured in duplicate.
Immunocytochemistry (ICC)
Cells were grown on Lab-Tek II chamber slide (Nunc), rinsed in
PBS, fixed in 4% paraformaldehyde for 20 min, and rinsed again in
PBS.Thecellswereincubatedforovernightat4uCwithmouseanti-
human-albumin antibody (1:200, R&D system) that does not have
cross-reactivity with bovine albumin, rabbit ant-Iba1 antibody
(1:200, WAKO pure chemical industries) and rabbit ant-CD11b
antibody (1:200, Abcam). The cells were rinsed in PBS and
incubated for 1 hr at room temperature with tetramethylrhodamine
isothiocyanate (TRITC)-conjugated anti-mouse IgG (1:500, Mo-
lecular Probes) and fluorescein isothiocyanate (FITC)-conjugated
anti-rabbit IgG (1:500, Molecular Probes). After wash in PBS,
coverslips were mounted onto glass slides using Fluoroguard
Antifade reagent (Bio-Rad Laboratories), and examined under a
laser confocal fluorescence microscope (FV500, Olympus).
Immunohistochemistry (IHC)
IHC was performed as previously described [27]. Human fetal
(23 wks), adult and Alzheimer’s brain tissues were acquired from
the Brain bank of Seoul National University hospital. The use of
human brain tissues was approved by the institutional review
board of Clinical Research Institute, Seoul National University
hospital. Briefly, human adult, fetal brain tissues were fixed in 4%
paraformaldehyde in 0.1 M phosphate buffer, followed by
cryoprotection in 30% sucrose for overnight, and then 30 mm
sections were prepared on a cryostat (Leica CM 1900). Paraffin-
embedded 4 mm thick Alzheimer’s brain tissue sections were de-
paraffinized in xylene and rehydrated in a graded ethanol series.
Antigen retrieval was performed by immersing slides in citrate
Albumin Synthesis in Brain
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used to block non-specific binding. The tissue sections were
incubated for overnight at 4uC with mouse anti-albumin (1:100,
R&D system), rabbit anti-Iba1 (1:200, WAKO), rabbit anti-
CD11b (1:200, Abcam), rabbit anti-GFAP (1:200, Chemicon),
rabbit anti-MAP2 (1:200, Chemicon) and rabbit anti-MBP (1:200,
Chemicon). The tissues were rinsed in PBS and incubated for 1 hr
at room temperature with TRITC-conjugated anti-mouse IgG
(1:500, Molecular Probes) and FITC-conjugated anti-rabbit IgG
(1:500, Molecular Probes). After wash in PBS, coverslips were
mounted onto glass slides using Fluoroguard Antifade reagent
(Bio-Rad Laboratories), and examined under a laser confocal
fluorescence microscope (FV500, Olympus).
Immunoprecipitation of albumin
Cell lysates were prepared with RIPA buffer containing 1M Tris
(pH 7.5), 5M NaCl, 10% NP-40, 10% deoxycholate and protease
cocktail inhibitor. 1 mg of cell lysates were incubated with 100 ml
of anti-albumin Ab (Abcam)-conjugated Sepharose bead in 500 ml
PBS at 4uC for overnight. The Sepharose beads were precipitated
at 14,000 rpm for 5 min, and washed with 1 ml of washing buffer
containing 50 mM Tris–Cl and 500 mM NaCl (pH 8.0) for three
Figure 4. A proposed role of albumin secreted from human microglial cells in brain. a. Microglial cells synthesize albumin not only in
physiological condition, but also in pathological condition at an increased level. Images shown were taken from Alzheimer’s brain tissues. Iba1, a
microglial marker, and albumin were co-localized. b. Microglial cells synthesize albumin in a physiological condition. When activated (e.g., by Ab1–42),
microglial cells surround amyloid deposition, recruit/activate more microglial cells, and increase albumin synthesis and secretion. Albumin secreted
into tissue interstitial fluid inhibits Ab polymerization and increase its clearance.
doi:10.1371/journal.pone.0002829.g004
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polyacrylamide gel (Invitrogen), and Coomassie-stained.
Protein sequencing using tandem mass spectrometry
(MS/MS)
Gel bands were excised and subjected to in-gel digestion and
MS/MS as described before [28]. All MS/MS experiments were
performed using a Nano- LC/MS system consisting of a Surveyor
HPLC system and a 7-tesla Finningan LTQ-FT mass spectrom-
eter (Thermo Electron) equipped with a nano-ESI source. For
peptide identification, MS/MS spectra were searched using
Mascot version 2.0 (Matrix Science). Proteins that were identified
by one or more high scoring peptides were considered to be true
matches. The high scoring peptides corresponded to peptides that
were above the threshold in our Mascot search (expected,0.05,
peptide score.28). All high scoring MS/MS spectra were also
manually validated.
Statistical analysis
Results are presented as mean s.e.m. Two-tailed Student t-tests
were used for data analysis. A p-value of ,0.05 was considered as
the criteria of statistical significance.
Supporting Information
Table S1 Albumin peptides identified by MS/MS.
Found at: doi:10.1371/journal.pone.0002829.s001 (0.04 MB
DOC)
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